Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology.

Details

Ressource 1Download: 22987488.pdf (571.85 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_0B982F37FE27
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology.
Journal
Swiss Medical Weekly
Author(s)
Zanchi A., Lehmann R., Philippe J.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2012
Volume
142
Pages
w13629
Language
english
Notes
Publication types: Journal Article
WOS Document Type: Review
Abstract
Patients with diabetes are at risk of early renal function decline. Therefore, kidney function needs monitoring at least once per year. Once the glomerular filtration rate (GFR) is less than 60 ml/min, the pharmacokinetics of antidiabetic drugs may be altered. Sulfonylurea and glinide therapies are associated with a risk of hypoglycaemia which is increased in the presence of renal impairment. Most sulfonylureas must be discontinued once GFR is <60 ml/min. Some glinides may be continued beyond this threshold, in particular repaglinide, which may be used in dialysis patients. In the absence of comorbidities, metformin can be continued at lower doses until a GFR of 45 ml/min, but must be withdrawn in case of dehydration or during the administration of a nephrotoxic drug including dye for radiological investigations. Glitazones may worsen water and sodium retention in patients with renal impairment. The pharmacokinetics of all DPP-IV inhibitors except linagliptin are altered with impaired renal function. Only sitagliptin, saxagliptin and linagliptin may be used in advanced kidney disease, but experience is as yet very limited. GLP-1 agonists are contraindicated in moderate to advanced kidney disease.
Pubmed
Web of science
Open Access
Yes
Create date
11/10/2012 16:45
Last modification date
20/08/2019 12:33
Usage data